Jared Kaltwasser

Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.

The finding that basophil counts may have prognostic significance aligns with a growing body of research into basophils in myeloproliferative neoplasms.

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a higher percentage of regulatory T cells (Tregs).

Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal residual disease (MRD) status.

The findings suggest a role for assessment of variant-carrying status to predict disease progression in idiopathic pulmonary fibrosis (IPF).

The incidence of small cell lung cancer (SCLC) is projected to drop by 5.9% each year through 2050.

A deep learning generative model is capable of autonomously learning about idiopathic pulmonary fibrosis.

The genes are all associated with cellular senescence, which is believed to play an important role in the development of idiopathic pulmonary fibrosis (IPF).

Investigators used previous trial data to compare patients receiving the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) to a real-world cohort receiving standard therapy.

Patients with early-stage melanoma who experience relapse following wide local excision face worse survival outcomes.

Multi-hit TP53 mutations significantly worsened survival in patients with myeloproliferative neoplasms (MPNs) and acute myeloid leukemia (AML), revealing critical prognostic insights.

Venetoclax demonstrated impressive efficacy in octogenarians with CLL, although treatment management posed some challenges.

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

A teledermatology program in Georgia helped identify patients with skin lesions that warranted in-person follow-up with a physician.

The potential therapy for idiopathic pulmonary fibrosis is notable because not only was the small molecule discovered by artificial intelligence, but the drug’s target itself was, too.

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

A new analysis of obesity guidelines suggests more evidence is needed to develop stronger guidelines for the transition period between childhood and adulthood.

Real-world data show no significant differences in overall survival between patients with or without cytogenetic risk factors.

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small cell lung cancer (ES-SCLC), a study found.

A new report suggests a noninvasive means to evaluate portal hypertension in patients with BCR::ABL1-negative myeloproliferative neoplasms.

A meta-analysis suggests allogeneic stem cell transplantation (allo-SCT) should not be recommended following first-line autologous stem cell transplant (auto-SCT).

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

TP53 aberrations and circulating tumor DNA burden were found to be predictors of poor outcomes in high-risk patients with large B-cell lymphoma.

A new analysis suggests artificial intelligence algorithms are able to accurately assess lesion severity in patients with atopic dermatitis.

People with chronic lymphocytic leukemia (CLL) saw a 55% year-to-year increase in all-cause mortality in the early days of the pandemic, a Swedish study found.

A new device was able to distinguish between mild and very severe chronic obstructive pulmonary disease (COPD).

The findings suggest assessment of CD20 may be an important factor in determining treatment options in B-cell lymphomas.

The findings highlight the limits of risk stratification algorithms based on data from older patients.

New findings suggest that reducing the variant allele frequency of JAK2V617F should be a goal of treatment for polycythemia vera.

Elevated LDH and higher international prognostic index were also predictors of poor outcomes on bispecific antibodies, investigators found.